Kornimate/medical-research-clean huggingface dataset:
federal learning algorithm for an intelligent insulin decision system for dynamic glucose control in type 2 diabetic patients

Conditions: Diabetes

Summary: constructing an intelligent insulin decision-making system for dynamic glucose control in type 2 diabetes mellitus via a multicentre federated learning algorithm, comparing the performance of the federated learning model, the local model and the initial model, and evaluating their feasibility and safety.

constructing an intelligent insulin decision-making system for dynamic glucose control in type 2 diabetes mellitus via a multicentre federated learning algorithm, comparing the performance of the federated learning model, the local model and the initial model, and evaluating their feasibility and safety.

Eligibility criteria:
inclusion criteria: * type 2 diabetes inpatients receiving insulin therapy exclusion criteria: * use of insulin pumps or glucocorticoids during hospitalisation * less than two days of insulin therapy
evaluation of objective outcomes with the use of an activity tracker during the trial period of spinal cord stimulation

Conditions: Post-laminectomy Syndrome; Axial Back Pain

Summary: for this study the investigators will conduct five-day trial periods for spinal cord stimulator (scs) effectiveness-once a patient is deemed to be a possible scs candidate, the trial leads are implanted and they are asked to return to clinic in five days to evaluate the effectiveness of the trial. the primary outcome for this study will be a comparison of daily energy expenditure (ee), in units of kcal/day, prior to and after the trial implantation of the scs leads and external pulse generator. patients will wear the accelerometer device twenty-four hours a day for five days prior to the trial lead implantation to obtain baseline values, have the trial leads implanted in the procedure clinic, then continue to wear the accelerometer for another five days. baseline and post-scs energy expenditure values will be compared. the secondary outcomes for this study will be steps taken, hours of sleep, and oswestry disability index (odi, as described in appendix 1) during the pre and post trial implantation periods. scs itself is not a research procedure in this study, rather it is part of routine medical care for patients who would benefit from the procedure.


Eligibility criteria:
inclusion criteria: * patients presenting to the ucd chronic pain clinic with post-laminectomy syndrome and demonstrate signs of neuropathic axial back pain will be considered. exclusion criteria: * adults unable to consent, individuals who are not yet adults, pregnant women, patients unable to stop anticoagulation, and prisoners will be excluded. * pregnant patients will be excluded due to the risks of radiation exposure during scs procedures and prisoners will be excluded as our clinic does not receive referrals from prison populations at this time.
impact of nicotine on retinal vascularization

Conditions: Tabagism

Summary: the main hypothesis is the nicotine is associated with a modification of retinal micro-vascularization. patients will be recruited during their ophthalmologic consultation at the rothschild foundation, an oct-a will be realized and data relating to medical history, oral contraceptive intake and nicotine consumption via cigarette or e-cigarette data will be collected. the objective is to seek an association between retinal vascular density and inhaled nicotine intake.


Eligibility criteria:
inclusion criteria * for group of smokers: patient reporting active smoking for at least 3 months and at least 1 cigarette per day on average over a week * for group of vapers : patient using exclusively the electronic cigarette with a nicotine level of more than 6mg/ml for at least 3 months and at least 1 times per day on average over a week. * for group of no-smokers no-vapersnon-smoking and no vaping, for more than 6 months non-inclusion criteria: * caffeine intake within 2 hours prior to the oct-a exam * ametropia greater than + 3 dioptres of hyperopia or-3 dioptres of myopia * astigmatism greater than 2 dioptres * known retinal or retina vascular pathology

Keywords: oct-a smokers vapers non-smokers/non-vapers nicotine retinal micro-vascularization
interest of the peak of reticulocytes in chronic hemodialysis patients treated by mircera hemodialysis population

Conditions: Renal Insufficiency, Chronic

Summary: patients under hemodialysis treatment are mostly treated by erythropoietin (epo) through erythropoiesis stimulating agents (esa). the objective of esa treatments is to maintain the hemoglobin level in a therapeutic target around 11g/dl. the epo dose that is necessary to reach this target depends on numerous and imbricated factors such as age, associated pathologies, iron status, inflammation. as of today, there is no marker to predict the epo response and hemoglobin (hb) level is currently the only and late tool to assess the efficacy.

reticulocytes are immature red blood cells that are temporary present in the blood circulation. they are easily monitored on every automatic dosing machines. nevertheless, among the dialysis population, they are seldom used and attempt to define a normal reticulocyte level, attesting a correct medullar response to the administrated epo dose failed due to the timing of blood collection (corresponding to the nadir day of reticulocytosis). in a preliminary study, it has shown that reticulocyte count kinetics depends on esa's type, dose and administration frequency. reticulocyte kinetics were compared in three groups of stable dialysis patients, depending on their esa treatment. reticulocyte curves under a monthly mircera® treatment were different from the other esas, showing a high reticulocyte peak (av. 80 000 reticulocyte/ml) occurring on day (d)8-d10 after mircera® administration. on the contrary, at nadir's point (d20-d30 after injection), reticulocyte levels are low for all the patients, preventing from any interpretation of the reticulocyte level at monthly routine assessment. it looks as though it is the peak level of reticulocytes that should be used as a marker of esa response. therefore, monitoring of reticulocytes would support the therapeutic decision on the need to adapt the epo dose. the study is design to determinated the interest of the reticulocyte peak in the daily practice

Eligibility criteria:
inclusion criteria: * age\> or equal to 18 years * patients on hemodialysis or hemodiafiltration for at least 3 months * patient treated monthly by mircera® for at least one month * affiliate or enjoying a social security scheme * patients who received oral and written information about the study, with no objection to the use of personal data and having signed an informed consent form and written exclusion criteria: * patient who refused to give his written consent to the study * patients treated with another erythropoiesis stimulating agent * minor * pregnant or breastfeeding women * major under guardianship

Keywords: hemodialysis epo mircera
regular home-use of dual-light photodynamic therapy in the management of chronic stage iii-iv periodontitis

Conditions: Periodontitis Chronic Generalized Moderate; Periodontitis Chronic Generalized Severe

Summary: this study is designed to determine the efficacy of the lumoral method in chronic periodontitis with a targeted group of stage iii and iv periodontitis. improved supragingival plaque control can help to also sustain the subgingival plaque management in the long term. in addition, the method might have a photobiomodulation effect on periodontal tissues.

the lumoral treatment is a ce-marked medical device developed to provide a potent, targeted antibacterial action on dental plaque in a home environment. the device mechanism of action is antibacterial photodynamic therapy (apdt). the device is used by swishing a specially designed mouth rinse that strongly adheres to dental plaque. the plaque-adhered photoactive mouth rinse can be activated by a simple-to-use light applicator. preliminary results have shown promising anti-inflammatory responses in addition to plaque reduction.

Eligibility criteria:
inclusion criteria: * periodontal disease stage iii-iv, according to criteria the american academy of periodontology (aap) with at least 3 mm interdental clinical attachment level (cal) in the site of greatest loss. * ≥ 18 years old * presence of ≥20 teeth, including implants * agreement to participate in the study and to sign a written consent form * able to co-operate with the treatment protocol and avoid any other oral hygiene measures outside of the study protocol exclusion criteria: * grade a or c periodontitis * presence of any physical limitation or restriction that might restrict lumoral use * pregnancy or lactation * active smoking * medicated diabetes mellitus (dm) * any systemic disease (e.g., wound healing dysfunctions) that could alter the progression of periodontal disease * use of antibiotics within 4 weeks week prior study * periodontal treatment within 3 months prior study * removable major prosthesis or major orthodontic appliance * a need for a hopeless teeth extraction, or open cavities in need for immediate endodontic treatment

Keywords: lumoral lumorinse periodontitis anti-bacterial photodynamic therapy apdt plaque ammp-8 photobiomodulation
study of tissue and blood samples from patients with low-grade glioma

Conditions: Brain and Central Nervous System Tumors

Summary: rationale: studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. it may also help doctors predict how patients will respond to treatment. purpose: this research study is looking at tissue and blood samples from patients with low-grade glioma.

objectives: * evaluate the diagnostic and prognostic relevance of alterations of specific chromosomes and chromosomal regions including 7, 9p, 10p, 10q, 13q, 17p, 17q, 19q, 22q, x, and y, using pcr analysis of microsatellite repeats and fish. * evaluate the diagnostic and prognostic relevance of dna ploidy by flow cytometric analysis; compare with ploidy determination by fish. * assess the diagnostic and prognostic relevance of various markers of cellular proliferation and cellular function including flow cytometric determination of %s-phase, %g2m, and immunohistochemical evaluation of pcna, ki-67, and p53.

Eligibility criteria:
1. paraffin-embedded tumor tissue blocks of patients enrolled in ncctg 86-72-51 or 93-72-02 and who had the diagnosis of low-grade glioma. 2. patients who have the diagnosis of low-grade glioma with an available paraffin- embedded tumor tissue block enrolled in prospective ncctg and mayo studies.

Keywords: childhood low-grade cerebellar astrocytoma childhood low-grade cerebral astrocytoma childhood mixed glioma adult mixed glioma adult diffuse astrocytoma childhood oligodendroglioma adult oligodendroglioma
intravitreal diclofenac versus intravitreal ranibizumab for the treatment of diabetic macular edema.

Conditions: Diabetic Macular Edema

Summary: the study aims to compare the effect of intravitreal non steroidal anti inflammatory (diclofenac) versus the standard treatment of diabetic macular edema, intravitreal anti vascular endothelial growth factor (ranibizumab), measuring central macular thickness changes and best corrected visual acuity.

thirty eyes of diabetic patients with diabetic retinopathy with macular edema will be randomized using simple randomization method into two groups; a and b. group a will undergo intravitreal injection of 500µg diclofenac, repeated monthly for 3 months. electroretinogram will be performed before the injections, 4 weeks after first injection and 4 weeks after third injection to assess any risk of toxicity. colored photography and fundus fluorescein angiography will be done before the first injection to assess the extent of macular leakage at late phases, and to exclude cases with macular ischemia. optical coherence tomography will be done to measure the central macular thickness, before the first injection, and before each injection. visual acuity will be assessed before and after each injection. group b will undergo intravitreal injection of 0.5 mg ranibizumab, repeated monthly for 3 months. colored photography and fundus fluorescein angiography will be done before the first injection to assess the extent of macular leakage at late phases, and to exclude cases with macular ischemia. optical coherence tomography will be done to measure the central macular thickness, before the first injection, and before each injection. visual acuity will be assessed before and after each injection. all patients will be examined weekly for one month and then monthly for three months after the injection. at every visit, visual acuity, intraocular pressure, and a dilated fundus examination will be performed. all patients will be required to instill topical antibiotic gatifloxacin postoperatively 3 times per day for 5 days. patients will be warned about the signs and symptoms of complications (endophthalmitis, retinal detachment, vitreous hemorrhage, lens trauma) and asked to seek medical attention immediately.

Eligibility criteria:
inclusion criteria: 1. diabetic retinopathy with non tractional maculopathy, where central macular thickness is greater than 400µm, with and without cystic changes. 2. diabetes mellitus type one and two 3. best corrected visual acuity \> 0.1 logmar exclusion criteria: 1. patients treated with diclofenac, ranibizumab or bevacizumab in the past 3 months 2. patients with a history of branch or central retinal artery occlusion 3. patients without clear media and adequate pupillary dilation that allows proper fundoscopy and imaging, and patients who are not complaint with the regular visits. 4. visual significant cataract 5. evidence of vitreomacular traction or macular ischemia

Keywords: diclofenac ranibizumab diabetic macular edema
oxidative balance in opioid therapy

Conditions: Pain; Opioids

Summary: the oxidative - antioxidative balance is the crucial mechanism of opioid-induced immunomodulation. additionally, impairement of cognitive function during opioid therapy is another important side- effect. this phenomenon was clearly described in opioids abuse. this is interesting to evaluate the importance of this subjects in chronic pain patients. the aim of the study was to investigate the oxidative - antioxidative homeostasis and cognitive functions using serum total oxidative capacity (toc) and total antioxidative capacity (tac) tests and brain derivered neutrophic factor (bdnf) in patient with chronic non-cancer pain treated with opioids.

the project was approved in ethical committee and supported by medical university of bialystok (poland). the serum toc and tac measurements were performed in total group of 50 adult patients: study group - 36 patients with chronic low-back pain with opioids pharmacotherapy and control group - 14 patients, healthy volunteers. in study group anthropometric parameters, duration in opioid therapy, type of opioid, total dose, and form of application were registered.toc, tac, and bdnf measurements were performed using imanox, perox, bdnf tests (immundiagnostik, germany).data were analyzed using non-parametric tests.

Eligibility criteria:
inclusion criteria: * minimally, 6 months opioid therapy in chronic low- back pain exclusion criteria: * depression, steroids- local or systemic administration

Keywords: neurological condition opioids oxidative balance pain
the role of dry needling in hallux valgus

Conditions: Hallux Valgus; Myofascial Pain Syndrome

Summary: forty hallux valgus patients between the ages of 25-65 years, who are admitted to the physical medicine and rehabilitation clinic with the complaint of 1st metatarsophalangeal (mtf) pain and who meet the inclusion and exclusion criteria will be included. hallux valgus (hv) angles will be measured by dorsoplantar radiography before the patients start the study. the hv angle was measured as the angle between the bisection line of the first metatarsal bone and the first proximal phalanx. demographic data (age, gender, body mass index) will be recorded at the beginning of the study. then, the initial foot functional index (ffi) and visual analog scale (vas) scales were completed. the 1st mtf joint angle was also measured with a goniometer and recorded before starting the study. the patients were divided into two groups. the first group will be given 3 sessions of dry needling with seirin branded 0.6\*50 mm acupuncture needles for trigger point in the abductor hallucis muscle and toe-spread-out exercise. the second group will receive only toe-spread-out exercises. after starting the treatment, ffi and vas scores and 1st mtf angles will be measured and recorded weekly with a goniometer. at the end of the 3-week treatment, the ffi and vas scores of the participants will be re-evaluated after 1 week and 1 month, and the participants will be re-evaluated with a goniometer. the hallux valgus angle will be re-evaluated with x-ray 4 weeks after the end of the treatment.


Eligibility criteria:
inclusion criteria: * 25-65 years old with pain for more than 4 weeks * hallux valgus angle between 16-40 degrees * activity vas value above 4 exclusion criteria: * patients diagnosed with rheumatologic diseases * those diagnosed with diabetes mellitus (dm), those with chronic liver and kidney failure * those who received anti-inflammatory-analgesic treatment in the last 1 week * diagnosed with inflammatory rheumatic disease * those with a history of foot surgery * those with mid or hindfoot deformity * those with 1st mtf joint problems other than hallux valgus * those with a history of orthotic use * previous history of central or peripheral nerve damage, lower extremity neuropathy * those diagnosed with diabetes mellitus * those with cognitive impairment * unassisted mobilization
non-opioid prescriptions after arthroscopic surgery in canada (no pain)

Conditions: Knee Arthroscopy; Shoulder Arthroscopy

Summary: this is a randomized controlled trial of 200 patients between the ages of 18 and 65 years undergoing outpatient knee or shoulder arthroscopy. patients will be evaluated clinically at 2 and 6 weeks post-operatively. patients will be recruited from experienced arthroscopic surgeons at 3 hospital sites in hamilton, ontario. all research will be conducted according to international standards of good clinical practice and institutional research policies and procedures.


Eligibility criteria:
inclusion criteria: 1. patients undergoing outpatient knee or shoulder arthroscopy for any of the following procedures: acl reconstruction (with or without let), mpfl reconstruction (not including tto), chondroplasty, meniscectomy, meniscal repair meniscal transplant, microfracture, aci, fixation of unstable osteochondral lesion, subacromial decompression, rotator cuff repair, shoulder stabilization, superior capsule reconstruction, biceps tenotomy/tenodesis, capsular release, slap repair, diagnostic arthroscopy, irrigation and/or debridement, loose body removal, synovectomy 2. patients aged 18 years and older 3. patients who have the ability to speak, understand, and read english 4. provision of informed consent exclusion criteria: 1. patients who take or are on a home dose of an opioid medication (i.e. once daily or more) 2. patients involved in ongoing litigation or compensation claims for any injury (e.g. work safety insurance board, wsib) 3. patients involved in another research study that requires a specific post-operative pain control medication regimen 4. patients undergoing a knee or shoulder arthroscopy procedure that will likely have an operative time greater than 3 hours 5. patients who will undergo concomitant open surgery 6. patients who require overnight admission 7. patients with a contraindication or allergy to nsaids, acetaminophen, or morphine and hydromorphone 8. patients diagnosed with renal disease or cardiac disease 9. patients who are scheduled for/plan to have an additional surgical procedure during the 6-week follow-up period 10. patients who will likely have problems, in the judgement of the investigator, with maintaining follow-up 11. any other reason(s) the investigator feels is relevant for excluding the patient
mobile after-care support app: pilot rct

Conditions: Psychotic Disorder

Summary: the overall aim of this program of research is to refine and test the feasibility and acceptability of a newly developed mobile device-delivered app, called mobile after-care support (macs), to improve patients' coping and treatment adherence following a hospitalization related to their psychotic-spectrum disorder. the purpose of the proposed project is to establish the feasibility, acceptability, and preliminary effects of the app. to achieve the specific aims, the investigators will conduct a pilot randomized clinical trial (n = 60), with two treatment arms: macs vs. a mobile app attention control condition.


Eligibility criteria:
inclusion criteria: * recently hospitalized * dsm-5 criteria for psychotic-spectrum disorder based on structured clinical interview * 18 years or older * prescribed antipsychotic medication upon discharge * ability to speak and read english exclusion criteria: * substance use disorders at severe level * planned discharge to supervised living setting or participation in formal outpatient adherence programs * pregnancy or other medical condition contraindicating use of antipsychotic medications

Keywords: schizophrenia psychosis mhealth psychiatric hospitalization treatment adherence transitions of care coping skills psychosocial intervention
biomakers in tissue samples from patients with recurrent and/or metastatic squamous cell cancer of the head and neck previously treated with cisplatin with or without cetuximab

Conditions: Head and Neck Cancer

Summary: rationale: studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this research study is studying biomarkers in tissue samples from patients with recurrent and/or metastatic squamous cell cancer of the head and neck previously treated with cisplatin with or without cetuximab.

objectives: * to investigate the association between ercc1 expression and clinical outcomes (response rate, progression-free survival, and overall survival) in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who received cisplatin with versus without cetuximab on clinical trial ecog-e5397. outline: archived tumor tissue samples are analyzed for ercc1 expression by ihc. ercc1 levels (low or high) are assessed by an h-score and aqua, a quantitative ihc analysis. each patient's ercc1 level result is then compared with the patient's clinical outcome.

Eligibility criteria:
disease characteristics: * diagnosis of squamous cell carcinoma of the head and neck * recurrent and/or metastatic disease * received cisplatin with or without cetuximab on clinical trial ecog-e5397 * slides and blocks of tumor specimens available patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: recurrent metastatic squamous neck cancer with occult primary recurrent squamous cell carcinoma of the hypopharynx recurrent squamous cell carcinoma of the larynx recurrent squamous cell carcinoma of the lip and oral cavity recurrent squamous cell carcinoma of the nasopharynx recurrent squamous cell carcinoma of the oropharynx recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity stage iv squamous cell carcinoma of the hypopharynx stage iv squamous cell carcinoma of the larynx stage iv squamous cell carcinoma of the lip and oral cavity stage iv squamous cell carcinoma of the nasopharynx stage iv squamous cell carcinoma of the oropharynx stage iv squamous cell carcinoma of the paranasal sinus and nasal cavity recurrent verrucous carcinoma of the larynx recurrent verrucous carcinoma of the oral cavity stage iv verrucous carcinoma of the larynx stage iv verrucous carcinoma of the oral cavity recurrent salivary gland cancer salivary gland squamous cell carcinoma